Revaprazan
Clinical data | |
---|---|
Trade names | Revanex[1] |
ATC code | None |
Identifiers | |
| |
Synonyms | YH1885 |
CAS Number | 199463-33-7 |
PubChem (CID) | 204104 |
ChemSpider | 176801 |
Chemical and physical data | |
Formula | C22H23FN4 |
Molar mass | 362.44 g/mol |
3D model (Jmol) | Interactive image |
| |
|
Revaprazan (trade name Revanex) is a drug that reduces gastric acid secretion which is used for the treatment of gastritis.[2] It acts as an acid pump antagonist[3] (potassium-competitive acid blocker). Revaprazan is approved for use in Korea,[4] but is not approved in Europe or the United States.
References
- ↑ "Revaprazan". drugs.com.
- ↑ Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS (Oct 2010). "Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects". J Gastroenterol Hepatol. 25 (10): 1618–1625. doi:10.1111/j.1440-1746.2010.06408.x. PMID 20880169.
- ↑ Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS (Jan 2004). "Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers". J Clin Pharmacol. 44 (1): 73–82. doi:10.1177/0091270003261321. PMID 14681344.
- ↑ "Revaprazan Yuhan registered, South Korea (gastritis)". R & D Focus Drug News. September 25, 2006.
This article is issued from Wikipedia - version of the 7/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.